Aging in the eye predicts risk for kidney failure

Written By :  Dr. Kamal Kant Kohli
Published On 2022-12-26 14:30 GMT   |   Update On 2022-12-27 07:18 GMT

Retinal age is a validated biomarker of overall aging. It is defined as the difference between model-based retinal age and chronological age. At an advanced stage of chronic kidney disease (CKD), end stage kidney disease (ESKD) is characterized by severely decreased kidney function.

Researchers have found in a new study that retinal ageing shows efficacy as a potentially important, non-invasive biomarker to predict the risk of end-stage kidney disease (ESKD).

Further among  35,864 United Kingdom residents, every one-year increase in retinal age, assessed by retinal microvasculature changes, was associated with a 10% higher risk of incident kidney failure over 11 years of follow-up.

In the study  a deep learning prediction model used to characterize retinal age based on retinal images and chronological age. Cox proportional hazards regression models to investigate the association of retinal age gap with incident end-stage kidney disease (ESKD).

There is a pressing need to identify early predictive biomarkers of kidney failure, given its associated substantial morbidity and mortality. Ageing biomarkers have been associated with kidney failure but their clinical application has been challenging.

In this study recently published in the American Journal of Kidney Diseases (AJKD), retinal age gap (retina-predicted age minus chronological age), a clinically validated and artificial intelligence powered ageing biomarker based on retinal imaging, was associated with the future risk of kidney failure among UK residents.

This non-invasive and ageing biomarker may hold promise to assist in the identification of people at elevated risk for kidney failure.

The researchers concluded that Retinal age gap was significantly associated with incident ESKD and may be a promising non-invasive biomarker for of incident ESKD.

The limitation of the study includes limited generalizability because of the composition of participants in the UK Biobank study.

Reference

Shiran Zhang, Ruiye Chen, Yan Wang, Wenyi Hu, Katerina V. Kiburg, Junyao Zhang, Xiaohong Yang, Honghua Yu, Mingguang He, Wei Wang, Zhuoting Zhu,  Published:December 05, 2022DOI: https://doi.org/10.1053/j.ajkd.2022.09.018

Tags:    
Article Source : American Journal of Kidney Diseases

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News